Description

Technical Parameters

SR9009 (Rev-Erbα Agonist) 10mg 100 Tablets Core Information *

Pharmaceutical -grade raw materials | SR9009 (circadian rhythm regulator )

Chemical Name : (R)-2-((3,5-dimethyl-4-(4-(methylthio)phenyl)pyridin-2-yl)methylamino)-2-phenylethanol

CAS number : 1379686-29-8

EINECS number : To be assigned

Molecular formula : C₂₃H₂₆N₂O₂S

Molecular weight : 394.53

Melting point : 142-145°C

Appearance : White crystalline powder

Purity : ≥98% (HPLC test)

Core Properties

SR9009 is a Rev-Erbα nuclear receptor agonist . Due to its unique circadian rhythm regulation and metabolic control functions , it is widely used in metabolic disease research, athletic performance enhancement, and energy metabolism regulation .

✅ Circadian rhythm regulation mechanism :

Rev -Erbα activation : specifically activates the Rev-Erbα nuclear receptor and regulates circadian clock gene expression

Metabolic pathway regulation : affecting genes related to glucose metabolism, lipid metabolism, and energy balance

Mitochondrial biogenesis : Promotes mitochondrial generation and function

✅ Sports performance improvement effect :

Endurance Enhancement : Preclinical studies have shown a significant increase in exercise endurance by over 50%.

Energy metabolism optimization : improve energy utilization efficiency and increase exercise endurance

Recovery acceleration : reducing oxidative stress and inflammation after exercise

✅ Metabolism-enhancing properties :

Glucose regulation : Improves glucose tolerance and insulin sensitivity

Lipid metabolism regulation : reducing plasma triglyceride and low-density lipoprotein levels

Weight Management : Reduce fat accumulation and improve body composition

End Product Preparation Guidelines

1. Preparation of film-coated tablets (10 mg/tablet) :

Example recipe (for 1000 tablets):

SR9009 raw material: 10.0g

Microcrystalline cellulose: 80.0g

Lactose: 50.0g

Cross-linked carboxymethyl cellulose sodium: 8.0g

Magnesium stearate: 2.0g

Preparation process :

Raw material pretreatment : micronization (D90≤10μm)

Equal amount incremental mixing : gradually mix with diluent

Wet granulation : granulate with appropriate amount of purified water and dry in fluidized bed at 50℃

Granulation : 20 mesh sieve granules, add flow aids and lubricants

Tableting : 8mm round die, 8-10kN pressure tableting

Film coating : Enteric coating to improve bioavailability

Quality Control :

Content uniformity : RSD≤3% (HPLC detection)

Dissolution : ≥80% enteric release in 45 minutes (paddle method, 50 rpm)

Related substances : Single impurity ≤ 0.5%, total impurities ≤ 1.0%

Usage Protocol

1. Investigational Dosage Regimen :

Starting dose :

10 mg/day, taken twice a day (5 mg in the morning and 5 mg in the evening)

Tolerance assessment for 1 week

Maintenance dose :

20-30 mg/day, divided into 2-3 doses

Maximum study dose: no more than 50 mg/day

2. When to use :

Take in the morning :

Take the first dose 30 minutes before breakfast

Regulates daytime metabolic activity

Before exercise :

Take 60 minutes before exercise

Enhance exercise endurance and fat utilization

3. Cycle Management :

Short-term study : 4-8 weeks

Long-term study : 8-12 weeks (close monitoring of circadian rhythm changes is required)

Post -cycle observation : Continue to monitor the recovery of biological rhythms for 2-4 weeks after stopping the drug

Why choose SR9009 raw material ?

Innovative mechanism : The first metabolic modulator targeting the Rev-Erbα receptor

Multiple Benefits : Simultaneously improve metabolic health, athletic performance, and energy metabolism

Research value : It has important research value in the fields of metabolic diseases and sports medicine

Conclusion

SR9009 is a key tool in the study of circadian metabolic regulation. Through scientific formulation techniques , it can be formulated into various dosage forms, including oral enteric-coated tablets . Choosing us ensures high-purity raw materials, professional technical support, and comprehensive after-sales service .

Need anything, please contact us